Clinical features and serum beta 2-microglobulin levels in HIV-1 positive and negative Tanzanian patients with tuberculosis

Int J STD AIDS. 1995 Jul-Aug;6(4):278-83. doi: 10.1177/095646249500600411.

Abstract

Serum beta 2-microglobulin (beta 2M) rises in the later stages of HIV disease and has therefore been used to monitor progression to AIDS. However, little work has been done on patients co-infected with HIV and tuberculosis. We studied clinical features and serum beta 2-M in 35 Tanzanian patients treated for pulmonary tuberculosis (9 HIV-positive, 26 HIV-negative). The provisional WHO clinical definition of AIDS for use in Africa was fulfilled by 89% of the HIV-positive and 65% of the HIV-negative patients. Median serum beta 2-M on admission was slightly higher in HIV-positive (3.17 mg/l) than in HIV-negative (2.85 mg/l) patients. Serum beta 2-M fell during treatment in 17/24 (71%) of HIV-negative and 3/7 (43%) HIV-positive patients followed up for 6 months. We conclude that serum beta 2-M is frequently raised in active tuberculosis, and is therefore an unreliable indicator of the stage of HIV disease in co-infected patients. The WHO clinical definition of AIDS also proved unreliable in patients with tuberculosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS-Related Opportunistic Infections / blood*
  • AIDS-Related Opportunistic Infections / drug therapy
  • Adult
  • Antitubercular Agents / therapeutic use
  • Female
  • Follow-Up Studies
  • HIV Seronegativity*
  • HIV-1*
  • Humans
  • Male
  • Survival Analysis
  • Tanzania
  • Tuberculosis, Pulmonary / blood*
  • Tuberculosis, Pulmonary / drug therapy
  • beta 2-Microglobulin / metabolism*

Substances

  • Antitubercular Agents
  • beta 2-Microglobulin